Johnson, D C
Weinhold, N
Mitchell, J
Chen, B
Stephens, O W
Försti, A
Nickel, J
Kaiser, M
Gregory, W A
Cairns, D http://orcid.org/0000-0002-2338-0179
Jackson, G H
Hoffmann, P
Noethen, M M
Hillengass, J
Bertsch, U
Barlogie, B
Davis, F E
Hemminki, K
Goldschmidt, H
Houlston, R S
Morgan, G J
Article History
Received: 3 August 2015
Revised: 25 November 2015
Accepted: 30 November 2015
First Online: 16 December 2015
Competing interests
: GHJ has received honoraria from Celgene and Janssen-Cilag for speaking at educational meetings. GJM has participated in advisory boards for, received payment for lectures and development of educational presentations from, and has received travel support from Celgene, Novartis, Merck and Johnson & Johnson. FED has participated in advisory boards and spoken at meetings for Celgene, Ortho Biotech and Novartis, and has received travel support to attend meetings from Celgene and Ortho Biotech. JH has participated in advisory boards for Novartis, and has received travel support to attend meetings from Celgene, Janssen-Cilag and Takeda. HG has participated in advisory boards for, received payment for lectures and development of educational presentations from, and has received travel support from Celgene, Jassen-Cilag, Chugai, Novartis, Bristol-Myers Squibb, Millenium, Onyx, Amgen and Takeda. The remaining authors declare no conflict of interest.